Search results
-
Dr Daniel Hodson
... to characterise how new therapeutic agents that are entering trials for lymphoma may exert some of their effect though changes in ...
-
Professor Tim Eisen
... AstraZeneca, where I am currently responsible for oncology trials from first in man to Phase II. ...
-
Dr Elena Provenzano
... My primary interest is the translational aspect of clinical trials particularly in the neoadjuvant setting. Current trials include ARTemis, PARTNER, PRIMETIME and Neo-RT clinical trials in ...
-
Dr Finian Leeper
... properties and a close relative obatoclax is in clinical trials for multiple cancers. (b) synthesis of thiamin diphosphate (TPP) ...
-
Dr Gaia Schiavon
... biomarkers and study designs in ‘window of opportunity’ trials - Identification of newer imaging criteria for response assessment to ... RECIST’s limitations - Pharmacodynamics in clinical trials, disease linkage data to guide indication selection and targeted patient ...
-
Dr George Follows
... post, and I am developing a translational science / clinical trials interest. I am the clinical lead for CLL and lymphoma in Cambridge, and chair the Haematology Clinical Trials team. I am a committee member of the Cambridge Clinical Cancer Trials ...
-
Professor Grant Stewart
... a focus on developing and promoting surgery related clinical trials and translational research. Grant has a specific interest in optimising ... Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical ...
-
Dr Helen Morris
... and collaborated on a number of randomised controlled trials and other well-designed studies in the field of cancer and genetics in a ...
-
Dr Helen Hatcher
... lead investigator in several multicentre and international trials. ...
-
Dr Kelly Holmes
... setting up and co-ordinating the work for clinical research trials with the aim of developing novel imaging techniques in patients with ...
-
Dr Hanna Najgebauer
Open Targets Postdoctoral Fellow responsible for the development of new algorithms and computational tools for scoring cancer in vitro models based on their clinical relevance and covered genomic heterogeneity observed in primary disease.
